FARMINGDALE, N.Y., April 1, 2016 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, today announced four clinical abstract presentations were made at the 2016 Diabetic Limb Salvage Conference in Washington, D.C. The conference is taking place from March 31 through April 2, 2016. The new data demonstrated the value in using ultrasonic technology in debriding wounds.
In one study, SonicOne OR was shown to have a 90% success rate in the take of a skin graft when used to prepare the wound bed graft site. Dr. Peter Blume, DPM, FACFS, Assistant Clinical Professor of Surgery, Anesthesia and Orthopedics and Rehabilitation at the Yale School of Medicine commented, "SonicOne O.R. is quickly establishing itself as a new standard in wound bed preparation."
A second study demonstrated new evidence in the effectiveness of ultrasound in reducing bacterial load in infected wounds. A 105 reduction in bacterial count was measured immediately post treatment with Misonix's SonicOne O.R. "Bacterial infection is one of the leading causes for chronic wounds' failure to heal," said Dr. Michael Baruch, Chief Section of Plastic and Reconstructive Surgery, St. Joseph Hospital and Medical Center in New Jersey. "Data shows the SonicOne O.R. reduces the bacterial load allowing for the patient's wound to correctly heal."
"As the clinical evidence continues to build, the opportunity exists to establish SonicOne O.R. as the gold standard for wound debridement", stated Scott Ludecker, Senior Vice President of Global Sales & Marketing for Misonix. "The investment in our wound platform technologies are validated by this clinical evidence. We believe that strong clinical evidence such as that presented at the DLS Conference this year, will further enhance our SonicOne O.R. value proposition to our clinician customers as well as to hospital administrators."
Michael A McManus, Jr., President and Chief Executive Officer of Misonix, added, "We are committed to adding to the body of scientific evidence supporting all of our technologies at Misonix. The new data presented this week at DLS highlights this commitment to the surgical wound and burn surgeons and their patients. We are encouraged by this new data and look forward to sharing it with the healthcare community."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/four-clinical-abstracts-demonstrate-the-effectiveness-of-sonicone-or-in-wound-treatment-300244581.html
SOURCE Misonix, Inc.